The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way

Post a Comment
ANTIBODIES AND VACCINES ARE OUTDATED!................................................................................


NanoViricides, Inc (NNVC) is developing drugs that work safely and effectively even against variants; drugs that don't rely on immune systems…great for seniors and children!

Investors should keep their eyes on the global nanotechnology market, an arena that was valued at USD 3.78 billion in 2022 and is expected to reach USD 74.1 billion by 2032, growing at a CAGR of 34.5% during the forecast period. One emerging NYSE-traded company is standing out in the space as it develops antiviral therapies utilizing nanotechnology. Not long ago the company reported the successful completion of its Phase 1a/1b clinical trial for NV-387, its broad-spectrum antiviral drug. The trial, focusing on COVID-19 treatment, showed no adverse events. This year the company has a focus on advancing NV-387 through further clinical trials, expanding its treatment capabilities to address unmet medical needs. This includes RSV, the flu, and other viruses.

While NV-387 was developed in the context of the COVID-19 pandemic as a broad-spectrum pan-Coronavirus drug, the company has that it has strong antiviral activity against diverse types and families of viruses that include Coronaviruses, RSV, Influenza A, as well as Smallpox/Mpox in relevant animal models of these infections. Thus NV-387 could be the single drug that can combat all of the "tripledemic" viruses - Coronaviruses, RSV, and Influenza, an unmet medical need! Recently the company has found that the antiviral activity of NV-387 against RSV is strong enough to enable lethally infected animals to survive completely and not succumb to the infection.

Learn how NV-387 could possibly be able to cure RSV infection and change the landscape of treating viruses!

This message is a PAID ADVERTISEMENT for NanoViricides, Inc. (NYSE American: NNVC) from Interactive Offers. StockEarnings, Inc receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either NanoViricides, Inc. (NYSE American: NNVC) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc. (NYSE American: NNVC) on Small Caps Daily website for additional information about the relationship between Interactive Offers and NanoViricides, Inc. (NYSE American: NNVC).

Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.

StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS


Today's Bonus Content: Digitizing the $11T commodities sector with one tiny stock

Related Posts

There is no other posts in this category.

Post a Comment

Subscribe Our Newsletter